PDPs are the global leaders in developing new health technologies where lack of traditional market incentives have stalled progress

Since 2010, the coalition of twelve PDPs represented in this report have delivered nearly 80 new health technologies—treatments, vaccines, diagnostics, vector controls, and devices. These products have reached more than 2.4 billion people, mostly in low- and middle-income countries (LMICs).

Highlights of these innovations include the first ever drug approved for treatment of highly drug-resistant forms of tuberculosis (TB), a single dose treatment to prevent relapse of P. vivax malaria, and the first all oral cure for all stages of sleeping sickness.

These advances are concentrated in diseases of poverty where investment and innovation have long been stagnant. Market-driven incentives do not drive the development of lifesaving technology for these diseases that kill millions per year; PDPs, funders, and collaborating institutions achieve critical innovation and solutions that would otherwise